Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 8,953,474
  • Shares Outstanding, K 60,030
  • Annual Sales, $ 1,488 M
  • Annual Income, $ 396,830 K
  • 36-Month Beta 1.25
  • Price/Sales 6.02
  • Price/Cash Flow 16.77
  • Price/Book 4.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
146.83 +3.50%
on 05/18/17
163.75 -7.19%
on 04/28/17
-0.87 (-0.57%)
since 04/21/17
3-Month
130.25 +16.68%
on 03/07/17
163.75 -7.19%
on 04/28/17
+17.02 (+12.61%)
since 02/22/17
52-Week
95.80 +58.63%
on 11/04/16
163.75 -7.19%
on 04/28/17
+2.33 (+1.56%)
since 05/20/16

Most Recent Stories

More News
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Jazz Pharmaceuticals plc today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.

JAZZ : 151.97 (+1.89%)
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.

JAZZ : 151.97 (+1.89%)
Jazz Pharmaceuticals Has Returned 41.2% Since SmarTrend Recommendation (JAZZ)

SmarTrend identified an Uptrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on December 23rd, 2016 at $108.62. In approximately 5 months, Jazz Pharmaceuticals has returned 41.24% as of today's recent price...

JAZZ : 151.97 (+1.89%)
Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales

Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.

AGLE : 6.20 (-4.32%)
GALE : 0.56 (unch)
JAZZ : 151.97 (+1.89%)
VVUS : 1.08 (+3.85%)
Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results

Total Revenues Increased 12% to $376 Million

JAZZ : 151.97 (+1.89%)
Investor Network: Jazz Pharmaceuticals Plc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 9, 2017 / Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 4:30 PM Eastern Time.

JAZZ : 151.97 (+1.89%)
Uptrend Call Working As Jazz Pharmaceuticals Stock Rises 45.5% (JAZZ)

SmarTrend identified an Uptrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on December 23rd, 2016 at $108.62. In approximately 4 months, Jazz Pharmaceuticals has returned 45.54% as of today's recent price...

JAZZ : 151.97 (+1.89%)
Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?

Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

CNAT : 5.30 (+1.53%)
JAZZ : 151.97 (+1.89%)
IMGN : 5.16 (-1.71%)
FGEN : 26.60 (-0.56%)
Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy results from the global multicenter study of JZP-110 in adult patients with excessive sleepiness associated with narcolepsy. Based...

JAZZ : 151.97 (+1.89%)
Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017

Jazz Pharmaceuticals plc today announced that it will report its 2017 first quarter financial results on Tuesday, May 9, 2017, after the close of the financial markets. Company management will host a...

JAZZ : 151.97 (+1.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Support & Resistance

2nd Resistance Point 154.09
1st Resistance Point 153.03
Last Price 151.97
1st Support Level 150.18
2nd Support Level 148.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.